Product Pathways - Growth Factors/Cytokines
Human Transforming Growth Factor α (hTGF-α) #5495
Recombinant human TGF-α (hTGF-α) Val40-Ala89 (Accession #NP_003227) was produced in E. coli at Cell Signaling Technology.
Based on amino acid sequencing, greater than 50% of recombinant hTGF-α has a Met on the amino-terminal Val40 (MVVSH) and has a calculated MW of 5,683. The remainder starts at Val40 (VVSHF). DTT-reduced and non-reduced protein migrate as 5 kDa polypeptides.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-α. All lots are greater than 98% pure.
The bioactivity of recombinant hTGF-α was determined in a MCF-10A cell proliferation assay. The ED50 of each lot is between 0.25-1.0 ng/ml.
The purity of recombinant hTGF-α was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hTGF-α and staining overnight with Coomassie Blue.
The proliferation of MCF-10A cells treated with increasing concentrations of hTGF-α was assessed. After 24 hour treatment, cells were labeled with BrdU for 4 hours. BrdU incorporation was determined by ELISA and the OD450-OD650 was determined.
Western blot analysis of extracts from HeLa cells untreated or treated with hTGF-α for 10 minutes, using Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb #4407 (upper) and EGF Receptor Antibody #2232 (lower).
Less than 0.01 ng endotoxin/1 μg hTGF-α.
With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-α. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.
TGF-α is a member of the EGF family of proteins and is expressed by epithelial cells, keratinocytes, macrophages, and many tumor-derived cell lines (1-4). Soluble TGF-α is produced by proteolytic cleavage of a transmembrane precursor (5). TGF-α promotes cell proliferation and differentiation of a diverse array of cell types including cancer and neural cells (1,4,6). TGF-α binds to EGFR/ErbB1 and induces receptor dimerization and tyrosine kinase activation (7). TGF-α activates the MAPK pathways and involves Stat3 and Stat5 (1,6). Increased levels of TGF-α expression are associated with many cancers including breast cancer (1,8,9).
- Humphreys, R.C. and Hennighausen, L. (2000) Oncogene 19, 1085-91.
- Rappolee, D.A. et al. (1988) Science 241, 708-12.
- Xu, X. et al. (1999) Oncogene 18, 5554-62.
- Ciana, P. et al. (2003) J Biol Chem 278, 31737-44.
- Higashiyama, S. et al. (2008) Cancer Sci 99, 214-20.
- Song, J.I. and Grandis, J.R. (2000) Oncogene 19, 2489-95.
- Citri, A. and Yarden, Y. (2006) Nat Rev Mol Cell Biol 7, 505-16.
- Révillion, F. et al. (2008) Ann Oncol 19, 73-80.
- Masago, K. et al. (2008) Cancer Sci 99, 2295-301.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.